A shorter duration of dual-antiplatelet therapy following percutaneous coronary intervention: a meta-analysis of randomized clinical trials

29 August 2025 (07:00 - 18:00)

Organised by:

Sign in for access options

Sign in to view the resources

Sign in for access options

About the speaker

Doctor Thomas Fretz

Indiana University School of Medicine, Indianapolis (United States of America)

4 More presentations in this session

Presentation thumbnail

State-of-the-art lecture on adjunctive antiplatelet therapy for patients undergoing percutaneous coronary intervention

Professor D. Capodanno (Catania, IT)

Presentation thumbnail

Impact of antiplatelet pretreatment on stent thrombosis in patients undergoing PCI in real world practice: insight France PCI registry

Doctor G. Range (Chartres, FR)

Abstract Slides Video

Presentation thumbnail

Aspirin reloading before percutaneous coronary intervention on chronic aspirin therapy: reduced early ischemia without bleeding trade-off

Doctor W. Dai (Tianjin, CN)

Abstract Slides Video

Presentation thumbnail

12- vs. 1-month DAPT: comparative outcomes after aspirin cessation with HT supreme stent

Doctor T. Tsai (Galway, IE)

Abstract Slides Video

Access the full session

Session thumbnail

Adjunctive antiplatelet therapy for patients undergoing percutaneous coronary intervention

The Event

Event poster

ESC Congress 2025

29 August - 1 September 2025

You may be interested in

Congress Presentation

Following an acute coronary syndrome, the default duration of dual antiplatelet therapy should be 12 months - discussion

Congress Presentation

Following an acute coronary syndrome, the default duration of dual antiplatelet therapy should be 12 months: pro

Congress Presentation

DAPT, monotherapy, or more? Rethinking antithrombotic strategies after percutaneous coronary intervention

ESC 365 is supported by

novartis

Explore sponsored resources

ESC 365 is supported by

novartis

Explore sponsored resources